McLeod Ian 4

4 · Anika Therapeutics, Inc. · Filed Mar 11, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

Anika (ANIK) SVP Ian McLeod Receives 2,197 Shares; 639 Withheld

What Happened

Ian McLeod, SVP, CAO & Treasurer of Anika Therapeutics (ANIK), had 2,197 restricted stock units (RSUs) vest on March 9, 2026. The RSUs converted into 2,197 shares.
To cover tax withholding on the vesting, 639 shares were retained by the company at $14.96 per share (total withholding value $9,559). After withholding, McLeod received a net 1,558 shares.
This is a routine equity award vesting (not an open‑market buy or voluntary sale); the tax withholding is a standard cashless settlement.

Key Details

Transaction date: March 9, 2026; Form 4 filed March 11, 2026 (timely — within the required reporting window).
Vesting/conversion shown as derivative exercise/conversion (code M); tax withholding shown as payment of tax liability via share retention (code F).
Withheld shares: 639 at $14.96/share = $9,559 withheld to satisfy taxes.
Net shares delivered to insider: 2,197 − 639 = 1,558 shares.
Shares owned after the transaction: Not specified in the filing.
Relevant footnotes:
- F1: Each RSU converts to one share of common stock.
- F3: 639 shares were retained by the issuer to satisfy tax withholding for RSUs that vested on March 9, 2026.
- F4: These 2,197 shares represent the third and final annual installment of a 6,590‑RSU grant made March 9, 2023.
- F2 notes prior ESPP purchases (528 shares on 2025‑05‑14 and 616 shares on 2025‑11‑14) referenced in the filing.

Context

This was a vesting/settlement of RSUs (equity compensation). The company withheld shares to cover withholding taxes (a common cashless net‑settlement); it is not an indication of a discretionary open‑market sale or purchase by the insider.
Such award vestings are routine compensation events and do not necessarily signal the insider’s view of the stock.

Form 4

Period: 2026-03-09

SVP, CAO & Treasurer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-03-09+2,197→ 19,383 total
Tax Payment
Common Stock
[F3]
2026-03-09$14.96/sh−639$9,559→ 18,744 total
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-03-09−2,197→ 0 total
→ Common Stock (2,197 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
[F2]Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 528 shares purchased on May 14, 2025 and 616 shares purchased on November 14, 2025.
[F3]Reflects an aggregate of 639 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.
[F4]On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

Signature

/s/ Ian McLeod|2026-03-11

1 file